Inoviq Ltd · ASX:IIQ
Inoviq — Investor Presentation (October 2022)
13 slides from Inoviq's investor presentation, Oct 27, 2022
Slide 1: Investor Presentation
Investor Presentation For personal use only ASX: IIQ | 27 October 2022
Slide 2: Disclaimer
Disclaimer For personal use only This presentation has been prepared by INOVIQ Limited (“INOVIQ” or the “Company”) based on Actual results, performance or achievements could be significantly different from those expressed information available to it as at the date of this presentation. This presenta
Slide 3: About INOVIQ
About INOVIQ For personal use only Financial information (ASX:IIQ) • Developing next-generation exosome capture tools and Ordinary shares 92,018,702 precision diagnostics for cancer and other diseases Share price (26/10/22) A$0.550 Market capitalisation (26/10/22) A$50.6m • Proprietary technology pl
Slide 4: Products and pipeline
Products and pipeline For personal use only ASSAY CLINICAL PRODUCT INDICATION PLATFORM USE RESEARCH DEVELOPMENT DEVELOPMENT REGISTRATION hTERT1 Bladder Cancer ICC Adjunct to cytology In-market EXO-NET-RUO Exosome Capture Device Research tool In-market Exosome-OC2 (OCRF-7) Ovarian Cancer Multiomi
Slide 5: SubB2M: Improves specificity in cancer detection and monitoring
SubB2M | Improves specificity in cancer detection and monitoring For personal use only • SubB2M detects the pan-cancer biomarker, Neu5Gc, found at elevated levels in multiple human cancers1 • Applications for detection and monitoring of multiple cancers (breast, ovarian, prostate, pancreatic, melano
Slide 6: SubB2M: SPR test for cancer risk assessment
SubB2M | SPR test for cancer risk assessment For personal use only • POC data in case-control studies showed the SubB2M-based SPR test detected: o Ovarian Cancer at 100% sensitivity and 100% specificity across all stages (n = 69) 1,2 o Breast Cancer at 95% sensitivity and 100% specificity across all
Slide 7: SubB2M: Immunoassays for cancer monitoring
SubB2M | Immunoassays for cancer monitoring For personal use only • Initial assay design, prototype development and feasibility testing of SubB2M immunoassays by Griffith University3 • Agreement with ResearchDx (US-based contract diagnostics organization) to further develop and validate SubB2M-based
Slide 8: SubB2M: Development plan
SubB2M | Development plan For personal use only PROJECT PLAN CY2022 CY2023 Feasibility testing Assay development Retrospective clinical study 1 (diagnostic accuracy by cancer stage) Retrospective clinical study 2 (clinical performance for monitoring) Analytical validation Clinical validation LDT mar
Slide 9: EXO-NET: Exosome isolation tools
EXO-NET I Exosome isolation tools For personal use only • EXO-NET pan-exosome capture is a ‘research use only’ (RUO) product for isolation of exosomes from body fluids with speed, purity and yield advantages • Enables rapid, efficient and scalable isolation of enriched exosomes • US contract sales f
Slide 10: EXO-NET: Exosome-based diagnostics pipeline
EXO-NET I Exosome-based diagnostics pipeline For personal use only Collaboration with UQ to develop world-first exosome-based ovarian cancer screening test1 AA OCRF-7 OCRF-7 BB CA-125 • EXO-NET technology used for fast and accurate 1.0 1.0 1.0 1.0 and scalable exosome isolation 0.8 0.8 0.8 0.8 predi
Slide 11: Expected achievements and catalysts
Expected achievements and catalysts For personal use only 4Q CY2022 CY2023 ✓ Agreement with Nicoya to transfer, develop - SubB2M BC test results & evaluate SubB2M SPR test - SubB2M OC test results - Commence SubB2M clinical studies for BC - Secure LDT laboratory partner - Commence SubB2M clinical st
Slide 12: Investment proposition
Investment proposition For personal use only Innovative Patented Strong Compelling Company Technology Pipeline Results Commercialised Significant growth Experienced Strong cash Products Potential Leadership Position 12 |
Slide 13: Contacts
Contacts For personal use only INOVIQ Ltd Dr Leearne Hinch Chief Executive Officer 23 Normanby Road Notting Hill VIC 3168 e. lhinch@inoviq.com Australia m. +61 400 414 416 p. +61 3 9548 7586 e. info@inoviq.com w. www.inoviq.com 13 |